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Objective: Bevacizumab is an important component in the treatment of various cancers, and despite guidelines
recommending its use in both ovarian and cervical cancer, patient access to bevacizumab and other angiogenesis
inhibitors is limited. Biosimilars are large, structurally complex molecules that are intended to be highly similar to,
and treat the same condition(s) as, an existing licensed or approved (reference) biologic, with no clinically meaningful
differences in purity, potency and safety. This article summarizes the role of bevacizumab in the treatment paradigm of
ovarian and cervical cancer. We also discuss the potential role of biosimilars to bevacizumab, which may offer more
affordable options in the future treatment of gynecologic cancers.
Methods: Literature searches of PubMed and ClinicalTrials.gov databases were conducted. Regulatory and individual
pharmaceutical company web pages were also reviewed. Search terms included “biosimilar” and “bevacizumab,” and
these were used to identify information regarding biosimilar development, reporting results of biosimilar studies or
biosimilars in development.
Results: At present, four bevacizumab biosimilar candidates are undergoing comparative clinical assessment, with the
potential to increase access and offer efficiencies across healthcare systems.
Conclusions: It is anticipated that biologics such as bevacizumab will continue to play a key role in the treatment of
an array of gynecologic cancers. Biosimilars to bevacizumab are currently in development and have the potential to
increase access to medicines in a variety of settings, including gynecologic cancers.
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Bevacizumab (Avastin®) is a recombinant humanized
monoclonal immunoglobulin G1 antibody that binds to
the human vascular endothelial growth factor and blocks
its activity and angiogenesis [1]. Bevacizumab is the only
complex biologic therapy indicated for the treatment of
patients with cervical, epithelial ovarian and fallopian
tube cancer in the United States (Table 1) and Europe.
Bevacizumab is also approved for the treatment of
patients with metastatic colorectal cancer, non-small-cell
lung cancer (NSCLC) and metastatic renal cell cancer
[1, 2]. Additionally, it is indicated for the treatment of* Correspondence: ira.jacobs@pfizer.com
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for use in metastatic breast cancer in Europe [2].
It is expected that the use of bevacizumab in gyneco-
logic cancers will increase, given the recent approval (in
combination with carboplatin and gemcitabine) in
platinum-sensitive ovarian cancer in the United States
[3] and Canada [4]. However, patient access to bevacizu-
mab and other angiogenesis inhibitors is limited [5].
This is due to several factors, including insurance cover-
age, drug availability, supply and manufacturing, and
concerns regarding the cost-effectiveness of bevacizu-
mab for some patients [5].
Biologics are large, structurally complex medicinal
products. Their active ingredients are created by bio-
logical processes rather than chemical synthesis.
Although biologics cannot be replicated, it is possible tole is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Bevacizumab: approved indications in the United States [1]
Clinical indication Combination regimen Treatment setting
Metastatic colorectal cancer Intravenous 5-fluorouracil–based chemotherapy First- or second-line treatment
Metastatic colorectal cancer Fluoropyrimidine-irinotecan– or fluoropyrimidine-
oxaliplatin–based chemotherapy
Second-line treatment in patients who
have progressed on a first-line
bevacizumab-containing regimen
Non-squamous non-small-cell lung cancer Carboplatin and paclitaxel First-line treatment of unresectable, locally
advanced, recurrent or metastatic disease
Glioblastoma Monotherapy Adult patients with progressive disease
following prior therapya
Metastatic renal cell carcinoma Interferon alfa Adult patients
Cervical cancer Paclitaxel and cisplatin or paclitaxel
and topotecan
Persistent, recurrent or metastatic disease
Platinum-resistant recurrent epithelial ovarian,
fallopian tube or primary peritoneal cancer
Paclitaxel, pegylated liposomal doxorubicin
or topotecan
Adult patients
Platinum-sensitive recurrent epithelial ovarian,
fallopian tube or primary peritoneal cancerb
Carboplatin and paclitaxel or carboplatin
and gemcitabine chemotherapy (followed
by bevacizumab)
Adult patients who have relapsed ≥6
months following last treatment with
platinum-based chemotherapy
aEffectiveness based on improvement in objective response rate. No data available demonstrating improvement in disease-related symptoms or survival
with bevacizumab
bFDA approval granted on 6 Dec 2016 [3]
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lar to an already licensed or approved reference biologic
in terms of purity, safety and efficacy [6, 7]. Biosimilars
have the potential to increase patient access to biologic
medicines, such as bevacizumab, and this may subse-
quently improve clinical outcomes.
This article reviews the role of bevacizumab in the
treatment paradigm of ovarian and cervical cancer. We
also discuss the potential role of biosimilars to bevacizu-
mab, which may offer more affordable options in the
future treatment of gynecologic cancers.
Review
Literature searches of PubMed and ClinicalTrials.gov
databases were conducted. Regulatory and indi-
vidual pharmaceutical company web pages were also
reviewed. Search terms included “biosimilar” and
“bevacizumab,” and these were used to identify infor-
mation pertaining to biosimilar development, report-
ing results of biosimilar studies, or biosimilars in
development.
Bevacizumab in the treatment of gynecologic cancers:
an overview
Bevacizumab, in combination with chemotherapy, is an
important component of treatment of ovarian cancer.
Approval of combination bevacizumab for the treatment
of platinum-resistant recurrent epithelial ovarian or
fallopian tube cancer was based on the results of an
international, open-label, randomized study, AURELIA
(Avastin Use in Platinum-Resistant Epithelial Ovarian
Cancer), in patients with measurable ovarian cancer that
had progressed <6 months following platinum-basedtreatment [8]. Median progression-free survival (PFS)
was 6.7 months with bevacizumab (10 mg/kg every
2 weeks or 15 mg/kg every 3 weeks) plus chemotherapy
(weekly paclitaxel, pegylated liposomal doxorubicin or
topotecan) vs 3.4 months with chemotherapy alone
(P < 0.001). Objective response rate was 27.3% with
bevacizumab plus chemotherapy vs 11.8% with chemo-
therapy alone (P = 0.001). No statistically significant differ-
ence in overall survival (OS) was observed between the
two treatment regimens. Hypertension and proteinuria
were common adverse events in patients treated with
bevacizumab plus chemotherapy [8].
The United States Food and Drug Administration
(FDA) recently granted approval of bevacizumab for the
treatment of platinum-sensitive recurrent epithelial
ovarian, fallopian tube or primary peritoneal cancer [3].
Approval was based on the results of two randomized
Phase 3 studies. The Gynecologic Oncology Group
(GOG) -0213 study showed that median OS was
42.6 months with bevacizumab plus chemotherapy vs
37.3 months with chemotherapy alone (P = 0.056). The
GOG-0213 study also showed improvement in PFS with
bevacizumab plus chemotherapy (13.8 months) compared
with chemotherapy alone (10.4 months; P < 0.0001). In the
OCEANS (Ovarian Cancer Study Comparing Efficacy and
Safety of Chemotherapy and Anti-Angiogenic Therapy in
Platinum-Sensitive Recurrent Disease) study, median PFS
was 12.4 months with bevacizumab plus chemotherapy vs
8.4 months with chemotherapy plus placebo (P < 0.0001).
However, no statistically significant difference in OS was
observed between the two treatment groups. The adverse
events associated with bevacizumab in the GOG-0213 and
OCEANS studies were consistent with those observed in
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cell count with fever, low sodium, pain in extremity, low
platelet count, elevated protein in the urine, high blood
pressure and headache [3]. Bevacizumab, in combination
with a chemotherapy backbone, is also a key component
in the treatment of cervical cancer. Approval of combin-
ation bevacizumab for the treatment of persistent, recur-
rent or metastatic cervical cancer was granted on the
results of an international Phase 2 randomized trial [9].
Results from this study showed that bevacizumab plus
chemotherapy (cisplatin plus paclitaxel or topotecan) was
associated with increased OS (17.0 months) compared
with chemotherapy alone (13.3 months) (P = 0.004). Sig-
nificantly higher response rates were observed with beva-
cizumab plus chemotherapy (48%) compared with
chemotherapy alone (36%) (P = 0.008). In addition, bevaci-
zumab plus chemotherapy was associated with a higher
frequency of hypertension, thromboembolic events and
gastrointestinal fistulas, compared with chemotherapy
alone [9]. In summary, bevacizumab in combination with
chemotherapy is the mainstay of treatment for a variety of
gynecologic cancers.
Challenges and barriers to the use of bevacizumab in
clinical practice
A recent retrospective population-based study using the
Surveillance, Epidemiology, and End Results (SEER)-
Medicare database of 9491 women with epithelial
ovarian cancer showed that, despite strong evidence of
improved survival associated with therapy recommended
by National Comprehensive Cancer Network (NCCN)
guidelines, [10] over 70% of women receiving initial
treatment for epithelial ovarian cancer did not receive
treatment consistent with NCCN recommendations
[11]. Ultimately, this may adversely affect patient care
and is a serious global concern.
Despite the clinical success of bevacizumab in cancers
with a large global incidence, such as lung and colorectal
cancers, and clear guidelines recommending its use in
both ovarian [10] and cervical cancer, [12] there is a not-
able lack of patient access to bevacizumab. Disparities in
access to bevacizumab and other targeted therapies have
been reported in Europe, with some countries reporting
only occasional access to bevacizumab, or access for
only 50% of patients with ovarian cancer [5]. Therefore,
it is important to identify areas of inefficiencies and to
understand barriers to patient access.
Several factors, including healthcare system infrastruc-
ture, stage at diagnosis, population health and lifestyle
and availability of anticancer agents, can influence access
to cancer therapy. Issues related to insurance coverage,
treatment cost, drug availability, supply and manufactur-
ing may create barriers to the use of bevacizumab in many
countries worldwide. A survey conducted by the EuropeanSociety of Medical Oncology (ESMO) Consortium re-
ported budget and affordability issues, and problems with
the manufacture and supply of bevacizumab as the most
common factors leading to suboptimal access to beva-
cizumab in a variety of cancers [5].
Clinical trials demonstrated bevacizumab improves
PFS in patients with ovarian cancer [8] and OS in
cervical cancer [9]. Although bevacizumab with chemo-
therapy is more effective with regard to PFS than
chemotherapy alone, it is not a cost-effective, front-line
treatment regimen in the overall population of patients
with ovarian cancer (Table 2) [13]. Furthermore, ap-
proximately three-quarters of US oncologists do not
consider bevacizumab a “good value” treatment option
[14]. However, a recent analysis utilized results from the
AURELIA study of bevacizumab plus chemotherapy
versus chemotherapy alone in patients with platinum-
resistant recurrent ovarian cancer [8]. This analysis
concluded that bevacizumab was cost-effective in this
setting [15]. Taken together, it is clear that further studies
are needed to determine the cost-effectiveness of bevaci-
zumab in the real-world setting.
Bevacizumab will continue to remain an important
component in the treatment of gynecologic cancers as
well as other settings. In light of the limited access to
bevacizumab worldwide, additional treatment options
for gynecologic cancers are eagerly awaited.
Development of biosimilars and their potential benefits
Patents for bevacizumab will shortly expire in the United
States and Europe [16]. Biosimilars are large, structurally
complex molecules that are intended to be highly similar
to, and treat the same condition(s) as, an existing
licensed or approved (reference) biologic [6, 7]. Biosimi-
lars may offer increased treatment options for patients
and physicians and have the potential to optimize effi-
ciencies across healthcare systems worldwide. Additionally,
biosimilars may provide lower cost alternatives and there-
fore increase access to biologics and allow greater use of
biologic therapies, which may facilitate improved clinical
outcomes.
The aim of biosimilar development is not to re-establish
efficacy and safety, but to demonstrate similarity to the
reference biologic in terms of quality, safety and efficacy
(Fig. 1) [6, 7]. The development of biosimilars involves
biochemical, biophysical and functional comparative
studies, and detailed characterization of the potential bio-
similar. Together with comparative nonclinical, pharma-
cokinetic (PK), and comparative clinical trials, these data
comprise the “totality of the evidence” [6].
Biosimilars must have an identical primary amino acid
sequence and the same route of administration, strength
and type of administration as the reference biologic [6, 7].
Biosimilars are manufactured through a process of reverse
Table 2 Cost-effectiveness of bevacizumab in the front-line treatment of ovarian cancer [13]







PAC + CAR 2.5 milliona 10.3 monthsb Referent Addition of BEV and maintenance
BEV was not cost-effective
PAC + CAR + BEV 21.4 milliona 11.2 monthsb USD479,712 per
PFLY gained
(PAC + CAR + BEV) +
maintenance BEV





PAC + CAR + BEV












Use of BEV with standard first-line
taxane was not cost-effective in stage
III/IV ovarian cancer. May be suitable




PAC + CAR 535e 10.5b Referent For high-risk, advanced ovarian cancer
patients, ICER was almost USD170,000
per life-year saved






BEV bevacizumab; CAR carboplatin; ICER incremental cost-effectiveness ratio; LYG life-year gained; PAC paclitaxel; PFLY progression-free life-year;
QALY quality-adjusted life-year; USD United States dollars




eTotal cost per cycle
Dominated: BEV was more costly and less effective
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structural and functional characterization using state-of-
the-art technology and highly specialized techniques to
identify any differences between the proposed biosimilar
and the reference biologic, particularly those that may
alter the mechanism of action [17].
A series of analytical similarity assessments are con-
ducted to confirm identical amino acid sequences, similar
post-translational modifications and highly similar bio-
logic activity between the proposed biosimilar and the ref-
erence biologic. Analytical similarity forms the foundation
for similarity in safety and efficacy. In addition, aFig. 1 Development pathways for originator biologics and biosimilars: a di
pharmacodynamics, PK: pharmacokineticscomprehensive assessment of the structural and functional
similarity of the potential biosimilar and the reference bio-
logic is conducted using state-of-the-art techniques, physi-
cochemical methods and functional assays [17].
Regulatory agencies do not typically require extensive
nonclinical studies for the approval of biosimilars, although
this is assessed on a case-by-case basis [6, 7]. A comparative
clinical study is generally conducted in one therapeutic in-
dication to demonstrate that there are no clinically mean-
ingful differences in PK, pharmacodynamics (PD), efficacy
or safety, including immunogenicity, between the potential
biosimilar and the reference biologic. The goal of afferent way of thinking. Adapted from Kozlowski et al., 2012. PD:





Study objectives Key findings
Amgen ABP 215 NSCLC Functional similarity and PK equivalence •Similar functional characteristics
•Equivalent PK [26]
NSCLC Clinical equivalence of objective
response rate
•Clinical equivalence
•Similar safety and immunogenic profiles to
bevacizumab [20]
Biocad BCD-021 NSCLC PK and safety •Similar PK and safety [21]
NSCLC Overall response rate •Similar efficacy, safety and immunogenicity [22]
Boehringer
Ingelheim
BI 695502 NSCLC Efficacy and safety •Recruiting (NCT02272413)
mCRC Efficacy and safety •Recruiting (NCT02776683)
Pfizer PF-06439535 NSCLC Nonclinical evaluation •Similar structure and in vitro biological activity [24]
•Similar in vivo toxicology [24]
NSCLC PK and safety •PK similarity [25]
•Comparable safety profile [25]
NSCLC Comparative efficacy and safety •Ongoing (NCT02364999)
NSCLC non-small-cell lung cancer; PK pharmacokinetics
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tainty between the proposed biosimilar and the reference
biologic [6, 7]. Because all biologics, including biosimilars,
have the potential to trigger an immunogenic response,
which may alter the PK, efficacy or safety properties, [18]
the formation of antidrug antibodies is carefully monitored
throughout development and during postmarketing
surveillance.Biosimilars and the scientific basis of extrapolation across
indications
Extrapolation is a scientific and regulatory principle that de-
scribes the approval of a biosimilar for use in an indication
held by the reference biologic, which is not directly studied
in a comparative clinical trial with a biosimilar. Extrapola-
tion is key to the concept of biosimilarity and is based on
establishing a similar mechanism of action for the biosimi-
lar in various disease indications [6]. As well as reducing or
eliminating the need for studies in multiple indications, ex-
trapolation can potentially allow greater access to biosimi-
lars, with minimal delays in treatment. The concept of
extrapolation is supported by the US FDA and the Euro-
pean Medicines Agency (EMA) regulatory guidelines [6, 7].
However, the decision to extrapolate data from one indica-
tion to another is made on a case-by-case basis, with strong
scientific justification and the totality of evidence.
The mechanism of action of bevacizumab involves the
inhibition of vascular endothelial growth factor (VEGF),
which has an important role in tumor angiogenesis and
vascularization [1, 2]. Bevacizumab is an effective treat-
ment for a number of tumors and its mechanism of action
is independent of tumor site [1]. This forms the basis of
the scientific rationale for extrapolation of similarity data
across indications and may support the approval of bevaci-
zumab biosimilars in indications held by the reference bio-
logic without clinical studies in gynecologic indications.Bevacizumab biosimilar candidates in development
Four bevacizumab biosimilar candidates have completed
preclinical assessments and, based on the totality of
evidence, are currently undergoing comparative clin-
ical assessments (Table 3). ABP 215 (Amgen) showed
similar in vitro functional characteristics and equiva-
lent human PK to bevacizumab [19] and demon-
strated clinical equivalence and similar safety and
immunogenic profiles as bevacizumab in patients with
non-squamous NSCLC [20]. BCD-021 (Biocad)
showed similar PK and safety to bevacizumab in pa-
tients with NSCLC [21]. BCD-021 also demonstrated
similar efficacy, safety and immunogenicity to bevaci-
zumab in patients with advanced non-squamous
NSCLC [22]. A multicenter, randomized, double-blind
clinical trial is ongoing to evaluate the efficacy and
safety of BI 695502 (Boehringer Ingelheim) compared
with bevacizumab (in combination with chemother-
apy) in patients with advanced non-squamous NSCLC
(ClinicalTrials.gov, NCT02272413). PF-06439535 (Pfizer)
showed a similar structure and in vitro biological activity,
and a similar in vivo toxicologic and toxicokinetic profile
as bevacizumab [23, 24]. PF-06439535 also demonstrated
PK similarity and comparable safety profiles to beva-
cizumab in healthy male volunteers [25]. A trial of
PF-06439535 vs bevacizumab sourced in the EU in pa-
tients with advanced non-squamous NSCLC who have
not received prior chemotherapy is ongoing (Clinical-
Trials.gov, NCT02364999).Conclusions
It is anticipated that biologics such as bevacizumab will
continue to play a key role in the treatment of an array
of gynecologic cancers. Limited access to bevacizumab
and the lack of cost-effectiveness in some patients has
driven the need to develop safe and effective biosimilars
Monk et al. Gynecologic Oncology Research and Practice  (2017) 4:7 Page 6 of 7to bevacizumab, which have the potential to increase
access to medicines and offer efficiencies across health-
care systems.
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